Literature DB >> 19066635

Immunoresistant human glioma cell clones selected with alloreactive cytotoxic T lymphocytes: downregulation of multiple proapoptotic factors.

German G Gomez1, Michelle J Hickey, Richard Tritz, Carol A Kruse.   

Abstract

We previously reported the cellular, functional and cytogenetic characterization of immunoresistant (IR) 13-06-IR29 and 13-06-IR30 human glioma cell clones isolated after immunoselection with alloreactive cytotoxic T lymphocytes (aCTL). Relative to the 13-06-MG parental cells, both clones resisted aCTL lysis at multiple effector to target ratios; the resistant phenotype was maintained for 13-41 cell doublings after cloning and when selective pressure was removed; cross-resistance to other inducers of apoptosis/cell death was also observed (Gomez et al, 2006; Gomez and Kruse, 2007). In this study we further characterize the IR clones for factors that may contribute to the resistance. Data obtained by in-vitro quantitative morphologic and 7-amino actinomycin D flow cytometric assays revealed reduced apoptotic cell death when IR clones were coincubated with aCTL, relative to the parental cells. Since changes in apoptosis were observed, we examined the expression patterns of apoptosis-related genes in several extracts of parental cells and IR clones using pathway-specific cDNA microarray analysis. In general, the apoptotic factors were downregulated in the IR clones. From three separate extracts analyzed separately on microarrays, three factors, ATM, caspases 3 and 8, were statistically downregulated in both IR clones. Immunoblotting of the proteins confirmed the findings. Therefore, a possible mechanism for immunoresistance in gliomas may be achieved by the downregulation of one or more genes in the apoptotic pathway.

Entities:  

Year:  2008        PMID: 19066635      PMCID: PMC2597650     

Source DB:  PubMed          Journal:  Gene Ther Mol Biol        ISSN: 1529-9120


  36 in total

1.  Monoclonal antibody analysis of MHC expression in human brain biopsies: tissue ranging from "histologically normal" to that showing different levels of glial tumor involvement.

Authors:  L A Lampson; W F Hickey
Journal:  J Immunol       Date:  1986-06-01       Impact factor: 5.422

2.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

3.  Apaf1 is required for mitochondrial pathways of apoptosis and brain development.

Authors:  H Yoshida; Y Y Kong; R Yoshida; A J Elia; A Hakem; R Hakem; J M Penninger; T W Mak
Journal:  Cell       Date:  1998-09-18       Impact factor: 41.582

4.  Pilot study of local autologous tumor infiltrating lymphocytes for the treatment of recurrent malignant gliomas.

Authors:  K B Quattrocchi; C H Miller; S Cush; S A Bernard; S T Dull; M Smith; S Gudeman; M A Varia
Journal:  J Neurooncol       Date:  1999       Impact factor: 4.130

5.  Artificial-capillary-system development of human alloreactive cytotoxic T-lymphocytes that lyse brain tumours.

Authors:  C A Kruse; L T Beck
Journal:  Biotechnol Appl Biochem       Date:  1997-06       Impact factor: 2.431

6.  DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis.

Authors:  D A Thomas; C Du; M Xu; X Wang; T J Ley
Journal:  Immunity       Date:  2000-06       Impact factor: 31.745

Review 7.  Strategies using the immune system for therapy of brain tumors.

Authors:  N Virasch; C A Kruse
Journal:  Hematol Oncol Clin North Am       Date:  2001-12       Impact factor: 3.722

8.  Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.

Authors:  Linda M Liau; Robert M Prins; Sylvia M Kiertscher; Sylvia K Odesa; Thomas J Kremen; Adrian J Giovannone; Jia-Wei Lin; Dennis J Chute; Paul S Mischel; Timothy F Cloughesy; Michael D Roth
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

9.  Allogeneic tumor-specific cytotoxic T lymphocytes.

Authors:  J M Redd; A C Lagarde; C A Kruse; D Bellgrau
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Allelic imbalance of 12q22-23 associated with APAF-1 locus correlates with poor disease outcome in cutaneous melanoma.

Authors:  Akihide Fujimoto; Hiroya Takeuchi; Bret Taback; Eddy C Hsueh; David Elashoff; Donald L Morton; Dave S B Hoon
Journal:  Cancer Res       Date:  2004-03-15       Impact factor: 12.701

View more
  3 in total

1.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

2.  Implementing preclinical study findings to protocol design: translational studies with alloreactive CTL for gliomas.

Authors:  Michelle J Hickey; Colin C Malone; Kate E Erickson; German G Gomez; Emma L Young; Linda M Liau; Robert M Prins; Carol A Kruse
Journal:  Am J Transl Res       Date:  2012-01-10       Impact factor: 4.060

3.  Clinical and pathological implications of concurrent autoimmune thyroid disorders and papillary thyroid cancer.

Authors:  L L Cunha; R C Ferreira; M A Marcello; J Vassallo; L S Ward
Journal:  J Thyroid Res       Date:  2011-02-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.